Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (DAPA-HF)
The platform's marketing references approximately 16% average body weight reduction - attributable to clinical research on the semaglutide active ingredient, not the compounded preparation specifically
Sleep: Prioritize quality sleep, which supports the natural GH/IGF-1 axis [4]
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events
The current longitudinal literature is sparse and mixed, with some but not all studies reporting neurometabolite differences 14,15,16,17,18
Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults
